ERBB2 and neoplasm: We demonstrated additive anti-tumor activity by providing HDCD44v6.BiTE to CAR-T cells for dual antigen targeting and the ability to redirect HER2-specific CAR-T cells to kill HER2-negative tumor cells through CD44v6 engager, in contrast to a control HDCD19.BiTE even in an orthotopic (metastatic) mouse model [12].